{"name":"Aminex Therapeutics, Inc.","slug":"aminex-therapeutics-inc","ticker":"","exchange":"","domain":"aminex.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiugJBVV95cUxNU1BpVTFzWWhtUFVob3ZUX1NPMVZtYUpYLXRxS0x1SjBUbUdqcHdKRjkzbTFLel9VYWZfMzVGN1pjeTBlZTZTd09OYjF0THZQS05zdThYS19fTVdBTk0xMktNc3RWTEJLQXRiUlFoT00xcExRdUZhNGlySklJYUpveDZnb2VmUlFvb1g4bGRiU1RXZlpTWkhsTEZnT1UzTmh6Yk5VUy1RNE13RTVGN0tRMmF1NHhXZUJPTDdiSEUyR25DZHJzU1lwUEtsb1Q2MEdNMDlxS1Y4bk1jd05Jb2FXVWVCTmhWQXFQRF9kMGF3bjBZeGlqODBLVk1MQkExcndyQTJjczAwYlR1N3JWd2JLUTV0aWwtQjcwYTl6VjdNMHpYaVNtb3IwX2JyS0Y1ckUxOW1FRjEwSmZzdw?oc=5","date":"2026-03-12","type":"regulatory","source":"PR Newswire","summary":"Aminex Therapeutics Receives Second FDA Orphan Drug Designation for AMXT 1501 for Malignant Glioma Including DIPG - a Highly Aggressive Childhood Brain Cancer - PR Newswire","headline":"Aminex Therapeutics Receives Second FDA Orphan Drug Designation for AMXT 1501 for Malignant Glioma Including DIPG - a Hi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4AJBVV95cUxPTkZnM3J2ZmxUUVpfYVVXYVlkZFh2R040VTJOVXlPMDFmSWtDU2psZkNSSHJpcDNWT1YyV1k2OGZ2WXFLb1FIQ1ZnWXpxZGZLU3RUU3E3UzZoMXZjbEJFM24zMzZuNHlic0xGRHJzTTVmd2NpczNpeGJGR01HZEFublhlR0c3RWUtVXQzVjItd29qV0RsZVBzd00wMG03eERUZDgxSks0c3ZxQ1FSaDl2ZXFrMFViQ01yeG9hVnJoMWJaUzgzWWZicmk1STdqblNrQ0ZtanFKS2x5aVBmWFdVNmhXa0NlRHktWjZfZzZMN3YtREF0c0dGQ2RtZ0oxczJVRXpMX3A1QkxiTllWMV9rUkJ3MF9ZUFhoeTJKYWJGTklyUzdKU3IwMWJqNjU3YkdOWlB6NElKY0tLdUNlYS1xQ2VGVXRYeW9jTWVHeGcxeU1QOGdzNXd6dnhpYUdsdTlt?oc=5","date":"2026-02-04","type":"trial","source":"PR Newswire","summary":"Aminex Therapeutics Announces Multiple Sites Activated for Phase 1b/2 Clinical Trial of Novel Investigational Cancer Treatment AMXT 1501 and DFMO in Patients with Breast Cancer or Melanoma - PR Newswi","headline":"Aminex Therapeutics Announces Multiple Sites Activated for Phase 1b/2 Clinical Trial of Novel Investigational Cancer Tre","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE4xMHVKU1RITHdrZjVaUW1md05BUnU3UzhLMG82YXJHUWtDYnpMTDFEU051UjVWVlFDLTcyb3dpQTZQcTVnempQbmM0ekhjeVBPVlp2NDJyMHl1QllIR3ZF?oc=5","date":"2026-01-13","type":"trial","source":"nature.com","summary":"Therapeutic responses in patients with advanced NSCLC enrolled in early-phase clinical trials at MD Anderson - nature.com","headline":"Therapeutic responses in patients with advanced NSCLC enrolled in early-phase clinical trials at MD Anderson","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwJBVV95cUxPQmJncGFSeWV6ZkFjaWlUblZPWXl0clVrVWZwd0F1aFhBaWpxUGNMRFg5YndIcDNzNFloZEtXT3U4MjNHbzMzNHhSRmhiM0YxRWkzNS16ZDVfYV9sT1J1cXpOcW1haWpsNGE5VkZkLWMtX2FHc2hFZkZ3VUlVV2xXVUZfOXhQLTdqeEswTzZhcFhqY0ZkUjNuazhsQ2otSW81Qjh3WktSeXBTRVNmbFJvaFZ6dEk1VnRhLUdjZ0V1UnNvU20yZ0RGSDVFdTltQk9NOTB6MjVjSmVqT1JfemlxejVDTE1lWkJBQjlOUE5vTFU0TkNpYWRHY29ZSXotUzJRNjl1dU93ZExpOFMtTlZYcUpwSjBhYnVqVGZncHplaw?oc=5","date":"2025-10-02","type":"regulatory","source":"PR Newswire","summary":"Aminex Therapeutics Announces FDA Orphan Drug Designation Granted to AMXT 1501 in Combination with DFMO for the Treatment of Neuroblastoma - PR Newswire","headline":"Aminex Therapeutics Announces FDA Orphan Drug Designation Granted to AMXT 1501 in Combination with DFMO for the Treatmen","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTFAta0U2N3FIN0k4em5rcHdpNGdaS3BjSWRVVHZqTWt5ZExDTEFRWUlXbS1Cd29CbFRHMVlqS2xSaWttWjdiT19idlB1elRMYWxJMVhfRl9kT0I1dEVJU3NmcjNaY3VKVHhDczFmeWFYSE1Ianh2bnJuSVdXRQ?oc=5","date":"2025-01-23","type":"trial","source":"acsjournals.onlinelibrary.wiley.com","summary":"A phase 2 basket study of talabostat, a small-molecule inhibitor of dipeptidyl peptidases, administered in combination with pembrolizumab in patients with advanced solid cancers - acsjournals.onlineli","headline":"A phase 2 basket study of talabostat, a small-molecule inhibitor of dipeptidyl peptidases, administered in combination w","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiakFVX3lxTE52YndCeDNJYXJJLUNOcnFIMkZ3R3lwdzd0MW5ZeGRld1RFeXEycmpCS2xFX0Y1V0JMRUNyNmJtNjlCT2RZLXlXV2JzRjhNam43VzgxNno1djdFVFZHcFpVTWxmaWhPMHVBSnc?oc=5","date":"2024-02-24","type":"trial","source":"Wiley Online Library","summary":"Phase I study of sapanisertib (CB-228/TAK-228/MLN0128) in combination with ziv-aflibercept in patients with advanced solid tumors - Wiley Online Library","headline":"Phase I study of sapanisertib (CB-228/TAK-228/MLN0128) in combination with ziv-aflibercept in patients with advanced sol","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}